BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38587361)

  • 1. Update on FDG-PET in pediatric lymphoma.
    Kurch L; Kluge R
    Q J Nucl Med Mol Imaging; 2024 Mar; 68(1):58-69. PubMed ID: 38587361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The utility of FDG PET in diagnosis and follow-up of lymphoma in childhood.
    Sioka C
    Eur J Pediatr; 2013 Jun; 172(6):733-8. PubMed ID: 23559330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
    Specht L
    Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma.
    Pelosi E; Pregno P; Penna D; Deandreis D; Chiappella A; Limerutti G; Vitolo U; Mancini M; Bisi G; Gallo E
    Radiol Med; 2008 Jun; 113(4):578-90. PubMed ID: 18414808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [(18)F]FDG in childhood lymphoma: clinical utility and impact on management.
    Montravers F; McNamara D; Landman-Parker J; Grahek D; Kerrou K; Younsi N; Wioland M; Leverger G; Talbot JN
    Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1155-65. PubMed ID: 12192560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
    Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of diffusion-weighted MRI and [
    Morakote W; Baratto L; Ramasamy SK; Adams LC; Liang T; Sarrami AH; Daldrup-Link HE
    Eur Radiol; 2024 Jan; 34(1):643-653. PubMed ID: 37542653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDG-PET/CT in lymphoma.
    Juweid ME
    Methods Mol Biol; 2011; 727():1-19. PubMed ID: 21331925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma].
    Thill R; Neuerburg J; Fabry U; Cremerius U; Wagenknecht G; Hellwig D; Osieka R; Günther R; Büll U
    Nuklearmedizin; 1997 Oct; 36(7):234-9. PubMed ID: 9441282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.
    Cheson BD; Fisher RI; Barrington SF; Cavalli F; Schwartz LH; Zucca E; Lister TA; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
    J Clin Oncol; 2014 Sep; 32(27):3059-68. PubMed ID: 25113753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can fluorodeoxyglucose positron emission tomography/computed tomography avoid negative iliac crest biopsies in evaluation of marrow involvement by lymphoma at time of initial staging?
    Mittal BR; Manohar K; Malhotra P; Das R; Kashyap R; Bhattacharya A; Varma N; Varma S
    Leuk Lymphoma; 2011 Nov; 52(11):2111-6. PubMed ID: 21745169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Staging in childhood lymphoma: differences between FDG-PET and CT.
    Hermann S; Wormanns D; Pixberg M; Hunold A; Heindel W; Jürgens H; Schober O; Franzius C
    Nuklearmedizin; 2005 Feb; 44(1):1-7. PubMed ID: 15711722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Computerized tomography and F-18-FDG positron emission tomography in staging of malignant lymphomas: a comparison].
    Bumann D; de Wit M; Beyer W; Beese M; Lübeck M; Bücheler E; Clausen M
    Rofo; 1998 May; 168(5):457-65. PubMed ID: 9617362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy of whole-body 18F-FDP-PET for restaging malignant lymphoma.
    Mikosch P; Gallowitsch HJ; Zinke-Cerwenka W; Heinisch M; Pipam W; Eibl M; Kresnik E; Unterweger O; Linkesch W; Lind P
    Acta Med Austriaca; 2003; 30(2):41-7. PubMed ID: 12752087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma.
    Blum RH; Seymour JF; Wirth A; MacManus M; Hicks RJ
    Clin Lymphoma; 2003 Jun; 4(1):43-9. PubMed ID: 12837154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of FDG-PET imaging in the management of lymphoma.
    Kostakoglu L; Leonard JP; Coleman M; Goldsmith SJ
    Clin Adv Hematol Oncol; 2004 Feb; 2(2):115-21. PubMed ID: 16163171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of the standardized uptake value of pre-therapeutic (18)F-FDG PET in patients with malignant lymphoma.
    Ahmadzadehfar H; Rodrigues M; Zakavi R; Knoll P; Mirzaei S
    Med Oncol; 2011 Dec; 28(4):1570-6. PubMed ID: 20524086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of early response assessment in lymphoma with FDG-PET.
    MacManus MP; Seymour JF; Hicks RJ
    Cancer Imaging; 2007; 7(1):10-8. PubMed ID: 17766210
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Tamayo P; Martín A; Díaz L; Cabrero M; García R; García-Talavera P; Caballero D
    Rev Esp Med Nucl Imagen Mol; 2017; 36(5):312-321. PubMed ID: 28483374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma.
    Sasaki M; Kuwabara Y; Koga H; Nakagawa M; Chen T; Kaneko K; Hayashi K; Nakamura K; Masuda K
    Ann Nucl Med; 2002 Jul; 16(5):337-45. PubMed ID: 12230093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.